Corcept Therapeutics Files 8-K on Officer/Director Changes
Ticker: CORT · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1088856
Sentiment: neutral
Topics: leadership-change, corporate-governance, filing
TL;DR
Corcept's leadership team is changing, with new officers and directors potentially coming aboard.
AI Summary
On October 6, 2025, Corcept Therapeutics Incorporated filed an 8-K report. The filing indicates changes related to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing signals potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in key personnel and board composition can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Corcept Therapeutics Incorporated (company) — Registrant
- October 6, 2025 (date) — Date of earliest event reported
FAQ
What specific changes are being reported regarding directors and officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Are there any details on new compensatory arrangements for officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of information, suggesting such details are included.
What is the principal executive office address for Corcept Therapeutics?
The principal executive offices are located at 101 Redwood Shores Parkway, Redwood City, California 94065.
What is the SEC file number for Corcept Therapeutics?
The SEC file number for Corcept Therapeutics is 000-50679.
What is the SIC code for Corcept Therapeutics?
The Standard Industrial Classification (SIC) code for Corcept Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-06 16:36:06
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CORT The Nasdaq Stock Mar
- $5,708.33 — , Dr. Cannon will be paid a cash fee of $5,708.33 per month. The Agreement further provid
Filing Documents
- d817312d8k.htm (8-K) — 25KB
- 0001193125-25-231963.txt ( ) — 132KB
- cort-20251006.xsd (EX-101.SCH) — 3KB
- cort-20251006_lab.xml (EX-101.LAB) — 17KB
- cort-20251006_pre.xml (EX-101.PRE) — 11KB
- d817312d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 6, 2025 CORCEPT THERAPEUTICS INCORPORATED By: /s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer